Clinical Trials · NCT06976619
The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Mayo Clinic
- Enrollment
- 60
- Start date
- Oct 2025
- Locations
- 1 site, United States
- Primary endpoint
- Effect of exendin 9-39 on fasting glucagon secretion rate before and after liraglutide treatment